Valuation Scholar Rock Holding Corporation
Stocks
SRRK
US80706P1030
Biotechnology & Medical Research
|
Real-time Estimate
Cboe BZX
02:05:23 10/11/2026 HKT
|
5-day change | 1st Jan Change | ||
| 49.52 USD | +5.50% |
|
+16.38% | +13.37% |
| 10-28 | Scholar Rock Holding Insider Bought Shares Worth $11,999,922, According to a Recent SEC Filing | MT |
| 10-08 | Scholar Rock Resubmits Apitegromab Application in EU for Spinal Muscular Atrophy | MT |
Company Valuation: Scholar Rock Holding Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 872.1 | 467.6 | 1,356 | 4,046 | 4,493 | 5,717 | - | - |
| Change | - | -46.39% | 190.08% | 198.32% | 11.06% | 27.22% | - | - |
| Enterprise Value (EV) 1 | 709.3 | 414 | 1,304 | 3,918 | 4,270 | 5,400 | 5,306 | 5,327 |
| Change | - | -41.63% | 215.07% | 200.38% | 8.97% | 26.48% | -1.74% | 0.39% |
| P/E | -6.92x | -4x | -9.45x | -17.5x | -13.4x | -14.3x | -17.8x | -33.7x |
| PBR | 5.3x | 2.07x | 6.96x | 11x | 20.6x | 21.6x | 19x | 20.1x |
| PEG | - | 0.1x | 0.8x | -0.7x | -0.4x | -712.83x | 0.9x | 0.7x |
| Capitalization / Revenue | 46.3x | 14.1x | - | - | - | 1,007x | 40.3x | 14.9x |
| EV / Revenue | 37.7x | 12.5x | - | - | - | 952x | 37.4x | 13.9x |
| EV / EBITDA | -5.57x | - | - | - | -11.1x | -12.6x | -17.2x | -46.4x |
| EV / EBIT | -5.46x | -3.08x | -7.62x | -15.5x | -11.1x | -12.5x | -14.8x | -30.1x |
| EV / FCF | -5.37x | -3.1x | -8.98x | -19.5x | -14.2x | -19.5x | -22.5x | -55.7x |
| FCF Yield | -18.6% | -32.3% | -11.1% | -5.13% | -7.04% | -5.12% | -4.44% | -1.8% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -3.59 | -2.26 | -1.99 | -2.47 | -3.29 | -3.291 | -2.638 | -1.392 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 18.82 | 33.19 | - | - | - | 5.674 | 141.7 | 384.2 |
| EBITDA 1 | -127.3 | - | - | - | -383 | -429.2 | -308.8 | -114.9 |
| EBIT 1 | -129.9 | -134.4 | -171.3 | -252.1 | -384.6 | -432.8 | -357.8 | -177.2 |
| Net income 1 | -131.8 | -134.5 | -165.8 | -246.3 | -377.9 | -427 | -358.2 | -194 |
| Net Debt 1 | -162.8 | -53.53 | -51.84 | -127.7 | -223.8 | -316.5 | -410.4 | -390 |
| Reference price 2 | 24.84 | 9.05 | 18.80 | 43.22 | 44.05 | 46.94 | 46.94 | 46.94 |
| Nbr of stocks (in thousands) | 35,108 | 51,663 | 72,143 | 93,615 | 102,007 | 121,785 | - | - |
| Announcement Date | 7/3/22 | 7/3/23 | 19/3/24 | 27/2/25 | 3/3/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -14.26x | 951.68x | -12.58x | -.--% | 5.72B | |
| 17.43x | 6.68x | 12.81x | 1.71% | 66.7B | |
| 30.07x | 8.27x | 26.77x | 0.07% | 56.88B | |
| 38.45x | 6.84x | 20.45x | 0.85% | 56.53B | |
| 46.55x | 6.14x | 30.16x | -.--% | 46.49B | |
| 35.48x | 3.35x | 14.48x | -.--% | 44.8B | |
| -22.71x | 62.58x | -21.48x | -.--% | 41.59B | |
| 35.87x | 8.84x | 23.03x | 0.37% | 35.35B | |
| 41.46x | 8.08x | 26.8x | -.--% | 33.29B | |
| -69.81x | 13.21x | -71.01x | -.--% | 25.1B | |
| Average | 13.85x | 107.57x | 4.94x | 0.3% | 41.24B | |
| Weighted average by Cap. | 21.02x | 25.93x | 11.01x | 0.43% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- SRRK Stock
- Valuation Scholar Rock Holding Corporation
Select your edition
All financial news and data tailored to specific country editions
